Sign In
Buy ELDN
$3.81
-0.110 (-2.81%)
At Close: Jun 22, 2026
IRVINE, Calif., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing targeted medicines for pe
Eledon Pharmaceuticals to Present at Two Investor Conferences in September
04:05pm, Wednesday, 01'st Sep 2021
IRVINE, Calif., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing targeted medicines for p
Eledon Pharmaceuticals (ELDN) CEO David-Alexandre Gros on Q2 2021 Results - Earnings Call Transcript
09:16pm, Thursday, 12'th Aug 2021
Eledon Pharmaceuticals (ELDN) CEO David-Alexandre Gros on Q2 2021 Results - Earnings Call Transcript
Eledon Pharmaceuticals to Release Second Quarter Financial Results on Thursday, August 12, 2021
08:05am, Monday, 02'nd Aug 2021
Management to host conference call and webcast at 4:30 pm ET Management to host conference call and webcast at 4:30 pm ET
Eledon Pharmaceuticals Receives Health Canada Approval to Commence Human Trials to Evaluate AT-1501 in Kidney Transplantation
08:00am, Monday, 26'th Jul 2021
Interim data expected in late 2022 in a multicenter, open label study to replace tacrolimus with AT-1501
Eledon Pharmaceuticals Appoints Jan Hillson, M.D., to its Board of Directors
08:00am, Friday, 02'nd Jul 2021
IRVINE, Calif., July 02, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing targeted medicines for pe
Eledon Pharmaceuticals to Present at the Virtual Ladenburg Thalmann Healthcare Conference
04:07pm, Tuesday, 29'th Jun 2021
IRVINE, Calif., June 29, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing targeted medicines for pe
Eledon Pharmaceuticals (ELDN) CEO David-Alexandre Gros on Q1 2021 Results - Earnings Call Transcript
11:07pm, Thursday, 13'th May 2021
Eledon Pharmaceuticals (ELDN) CEO David-Alexandre Gros on Q1 2021 Results - Earnings Call Transcript
Eledon Pharmaceuticals to Release First Quarter Financial Results on Thursday, May 13, 2021
04:01pm, Tuesday, 04'th May 2021
Management to host conference call and webcast at 4:30 pm ET Management to host conference call and webcast at 4:30 pm ET
Eledon Pharmaceuticals Announces Update on Development Strategy for AT-1501 in Renal Transplantation
04:05pm, Monday, 26'th Apr 2021
IRVINE, Calif., April 26, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing targeted medicines for p
Moving Average Crossover Alert: Eledon Pharma (ELDN)
09:46am, Friday, 23'rd Apr 2021
Eledon Pharmaceuticals (ELDN) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.
Eledon Pharmaceuticals Continues to Bolster Leadership Team with Addition of Two More Key Executives
04:05pm, Monday, 19'th Apr 2021
David Hovland, Ph.D., to serve as Chief Regulatory Officer and Bryan Smith, J.D. as General Counsel, Corporate Secretary, and Chief Compliance Officer David Hovland, Ph.D., to serve as Chief Regulator
Eledon Pharmaceuticals Reports Fourth Quarter and Full-Year 2020 Operating and Financial Results
04:05pm, Tuesday, 30'th Mar 2021
Continued enrollment in Phase 2 clinical trial of AT-1501 in amyotrophic lateral sclerosis (ALS)
